Cargando…

CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease

Minimal change disease (MCD) is the most common cause of idiopathic nephrotic syndrome in children, and it is well known for its multifactorial causes which are the manifestation of the disease. Proteinuria is an early consequence of podocyte injury and a typical sign of kidney disease. Steroid-sens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teh, Yoong Mond, Lim, Soo Kun, Jusoh, Norhana, Osman, Kahar, Mualif, Siti Aisyah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806396/ https://www.ncbi.nlm.nih.gov/pubmed/33506028 http://dx.doi.org/10.1155/2021/6671552

Ejemplares similares

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Predictability of Urinary CD80 in the Relapse of Primary Nephrotic Syndrome
por: Liao, Juan, et al.
Publicado: (2017)

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2016)

Engineering and Validation of a Vector for Concomitant Expression of Rare Transfer RNA (tRNA) and HIV-1 nef Genes in Escherichia coli
por: Mualif, Siti Aisyah, et al.
Publicado: (2015)

Production and purification of polymerization-competent HIV-1 capsid protein p24 (CA) in NiCo21(DE3) Escherichia coli
por: Teow, Sin Yeang, et al.
Publicado: (2013)

Abatacept in Steroid-Dependent Minimal Change Disease and CD80-uria
por: Isom, Robert, et al.
Publicado: (2019)

Microfluidics-based skin irritation test using in vitro 3D angiogenesis platform
por: Jusoh, Norhana, et al.
Publicado: (2019)

Frequently Relapsing Post-COVID-19 Immune Thrombocytopenia
por: Serrano, Claudia, et al.
Publicado: (2021)

Reuse of Explanted Pacemakers: An Option for Economically Underprivileged Patients in Developing Countries
por: Francis, Johnson, et al.
Publicado: (2007)

Treatment options for relapsed Waldenström's Macroglobulinemia
por: Grunenberg, Alexander, et al.
Publicado: (2019)

Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor
por: Sato, Takashi, et al.
Publicado: (2022)

CD80 and CTLA-4 as diagnostic and prognostic markers in adult-onset minimal change disease: a retrospective study
por: Zhao, Bing, et al.
Publicado: (2018)

Urinary CD 80 in Nephrotic Syndrome: A Biomarker to Distinguish Minimal Change Disease From Other Glomerular Diseases
por: Mishra, Om P.
Publicado: (2020)

Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease
por: Iwabuchi, Yuko, et al.
Publicado: (2018)

Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
por: Frontzek, Fabian, et al.
Publicado: (2022)

Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Xue, Cheng, et al.
Publicado: (2020)

Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome
por: Al-Akash, Samhar, et al.
Publicado: (2005)

Autoantibodies against CD80 in patients with COPD
por: Luo, Xu Min, et al.
Publicado: (2016)

Tozinameran: Relapse of minimal change disease
Publicado: (2022)

Future options for CERN
por: Rubbia, Carlo
Publicado: (1989)

LEP and future options
por: Schopper, Herwig Franz
Publicado: (1984)

Future therapeutic options
por: Reuser, Arnold
Publicado: (2013)

Patients with primary focal segmental glomerulosclerosis with detectable urinary CD80 are more similar to patients with minimal change disease in clinicopathological features
por: Gong, Xiaojie, et al.
Publicado: (2023)

Current and Emerging Treatment Options for Patients with Relapsed Myeloma
por: Castelli, Roberto, et al.
Publicado: (2013)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
por: Wagner, Alex H., et al.
Publicado: (2018)

Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome
por: Casiraghi, Federica, et al.
Publicado: (2023)

CD80 Costimulation Is Essential for the Induction of Airway Eosinophilia
por: Harris, Nicola, et al.
Publicado: (1997)

Gallbladder cancer: current and future treatment options
por: Zhou, Yanzhao, et al.
Publicado: (2023)

Ethyl 4-(tert-butylamino)-3-nitrobenzoate
por: Mohd. Maidin, Siti Marina, et al.
Publicado: (2008)

A Case of Frequently Relapsing Minimal-Change Nephrotic Syndrome with Steroid-Induced Psychiatric Syndrome Treated by Low-Dose, Short-Term Steroid Therapy in Combination with Cyclosporine
por: Kondo, Isao, et al.
Publicado: (2020)

CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis
por: Scarpa, Marco, et al.
Publicado: (2015)

Usefulness of the cytokines expression of Th1/Th2/Th17 and urinary CD80 excretion in adult-onset minimal change disease
por: Chen, Ping, et al.
Publicado: (2020)

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
por: Kleinpeter, Patricia, et al.
Publicado: (2019)

Options for Future Colliders at CERN
por: Ellis, Jonathan Richard, et al.
Publicado: (1998)

Future options for optical links
por: Vasey, François
Publicado: (2007)

Options, futures, and other derivatives /
por: Hull, John, 1946-
Publicado: (1997)

The Eurodollar futures and options handbook
por: Burghardt, Galen
Publicado: (2013)

Options for the beginner and beyond: unlock the opportunities and minimize the risks
por: Olmstead, W Edward
Publicado: (2006)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fq0700ui0rer50r95dc212ev0c